In this video, we take an in-depth look at the recently FDA-approved antipsychotic, KarXT, also known by its brand name Cobenfy. This new drug represents a major breakthrough in schizophrenia treatment because, unlike traditional antipsychotics, it doesn’t rely on blocking dopamine receptors. Instead, KarXT works through a muscarinic agonist mechanism, making it a completely different approach to managing schizophrenia and other psychotic disorders.
We understand that you might not have time to read everything. That's why we're offering a special limited-time deal: subscribe to two newsletters of your choice and get 15% off the regular price!
In this video, we explore the use of alpha-2 agonists in the treatment of ADHD, specifically focusing on guanfacine ER (Intuniv) and clonidine ER (Kapvay). These non-stimulant ADHD medications have become viable options for patients who may not tolerate stimulants or have comorbid conditions that make stimulant medications less effective or problematic.
In this video, Dr. Chris Aiken, Editor-in-Chief of The Carlat Psychiatry Report, provides a comprehensive review of Gepirone, also known as Exxua, a newly FDA-approved antidepressant for major depressive disorder in adults. Gepirone is unique due to its classification as an azipirone, a class of medications that work as serotonin 5-HT1A receptor agonists.
Medication preauthorizations are essential but often frustrating, especially for psychiatric prescriptions. This article offers strategies to reduce revisions, ultimately streamlining the process.
In this video, we aim to break down where the safe upper limits lie for stimulant dosing, what to consider when increasing doses, and why crossing certain thresholds can lead to serious risks.
We start by discussing why increasing stimulant doses beyond a certain point can be dangerous.
In this video, we explore the potential of L-Methylfolate as a vital supplement in depression treatment. L-Methylfolate is a form of folate, a naturally occurring B-vitamin, and is often used to enhance the effects of traditional antidepressants.
In this video, we explore the latest breakthroughs in antidepressant augmentation, showing how personalized medicine can enhance outcomes for patients with various forms of depression. Whether your patient is facing anxious depression, depression with insomnia, or psychotic depression, this video offers evidence-based strategies that incorporate augmenation options such as lithium for depression, esketamine for depression, and quetiapine for depression.
Vilazodone, also known by its brand name Viibryd, became available as a generic in June 2022 after 11 years of market exclusivity. With the introduction of the Viibryd generic, the price of this multimodal antidepressant has significantly decreased, making it more accessible. However, the critical question remains: is vilazodone worth prescribing?
This video breaks down the findings from a meta-analysis of randomized controlled trials, examining how aripiprazole dosage impacts patient outcomes in clinical depression treatment.
RSS
-_-Benefits-Side-Effects-and-Review-of-Trials_Thumb.jpg?height=400&t=1727890706&width=600 "What You Need to Know About Gepirone (Exxua) _ Benefits, Side Effects, and Review of Trials_Thumb.jpg")
_-The-Breakthrough-Antipsychotic-That-Could-Change-Everything.jpg?1729528747 "KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg")
